`Pegasys' hot on the heels of standard hepatitis C therapy

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1295, 2001-01, pp. : 10-11

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Peginterferon -2a (40kD) [Pegasys ® ] Improves HR-QOL Outcomes Compared with Unmodified Interferon -2a [Roferon ® -A]: In Patients with Chronic Hepatitis C

By Rasenack J.

PharmacoEconomics, Vol. 21, Iss. 5, 2003-01 ,pp. : 341-349

Adis International

Access to resources Recommend Favorite

Perspectives in therapy for hepatitis C

By Vento Sandro Cainelli Francesca Temesgen Zelalem

Expert Opinion on Investigational Drugs, Vol. 17, Iss. 11, 2008-11 ,pp. : 1635-1639

Informa Healthcare

Access to resources Recommend Favorite

Editorial [Hot Topic: Acute Hepatitis C: Epidemiology, Pathogenesis and Therapy (Executive Editor: Paolo Fabris) ]

Current Pharmaceutical Design, Vol. 14, Iss. 17, 2008-06 ,pp. : 1644-1645

Bentham Science Publishers

Access to resources Recommend Favorite

New horizons in hepatitis C therapy

Inpharma, Vol. 1, Iss. 1265, 2000-01 ,pp. : 11-12

Adis International

Access to resources Recommend Favorite

Future trends in hepatitis C therapy

By Cornberg Markus Manns Michael

Future Virology, Vol. 1, Iss. 1, 2006-01 ,pp. : 99-107

Future Medicine

Access to resources Recommend Favorite